Lisata Therapeutics, Inc. · NASDAQ:LSTA

Lisata Therapeutics — Marea Therapeutics — Investor Presentation (September 2026)

25 slides from Lisata Therapeutics's investor presentation, September 2026

  1. Slide 1: Marea Therapeutics

    September 2026 Marea Therapeutics Transformative cardioendocrine therapies ©2023 Marea Therapeutics 1

  2. Slide 2: Forward Looking Statements & Disclaimers

    Forward Looking Statements & Disclaimers This presentation has been prepared by the Company based on information and data which the Company considers reliable, but no reliance shall be placed on, and no representation or warranty, express or implied, whatsoever is or will be given by the Company or

  3. Slide 3: Rapid Path to Value Creation

    Rapid Path to Value Creation Two potentially first-in-class assets with best-in-disease potential in large addressable markets MAR001/5 ~70% TG reduction3 Clean metabolic Severe >3M US patients¹ Phase 2b sHTG POC profile >$10B market Hypertriglyceridemia At risk of acute pancreatitis; (subgroup with

  4. Slide 4: Advancing a Late-Stage Cardioendocrine Pipeline Toward Potential 2026-27 Value Inflections

    Advancing a Late-Stage Cardioendocrine Pipeline Toward Potential 2026-27 Value Inflections Molecule Target Indication Disc IND-E Ph1 Ph2 Ph3 Anticipated Near-term Milestones MAR001 Phase 2b TYDAL (mHTG/sHTG) Q2 2026 ✓ • Phase 2/2b 12-week data Cardiometabolic H2 2026 • Phase 2/2b 24-week data MAR001

  5. Slide 5: MAR005 for sHTG

    • Section IV MAR005 for sHTG Potent sHTG candidate with a clean metabolic profile ©2023 Marea Therapeutics 5

  6. Slide 6: Recurrent Pancreatitis in sHTG: A Life-Altering Condition with Limited Options

    Recurrent Pancreatitis in sHTG: A Life-Altering Condition with Limited Options >3 million Americans; $9B in healthcare costs, no approved prevention therapies until recently The Unmet Need Until Recently: Limited Options Limited Generic Options The Critical Gap • >3M Americans with sHTG face recurre

  7. Slide 7: APOC3 Inhibition: New Treatments Driving a Potential Multi-Billion Dollar Opportunity

    APOC3 Inhibition: New Treatments Driving a Potential Multi-Billion Dollar Opportunity First class of medications to demonstrate acute pancreatitis (AP) event reduction Next-Gen Rx sHTG Opportunity PROJECTED US MARKET 60-80% TG reduction >$10B — dramatically superior to fibrates or omega-3 fish oil 7

  8. Slide 8: APOC3 Class Comes at a Cost: Deterioration in Glycemia / Exclusion of the 30%

    APOC3 Class Comes at a Cost: Deterioration in Glycemia / Exclusion of the 30% Patients with Poorly Controlled T2DM HbA1c +0.3 despite Rx; Hyperglycemia AEs were most common Plozasiran AE1,4; Plozasiran excluded HBA1c>9 Population Drug / Study TG Reduction Adverse Effects on Glycemic Control (in T2DM

  9. Slide 9: Biology and Genetics Support Inhibition of ANGPTL4 as Potential Best-in-Disease Profile

    Biology and Genetics Support Inhibition of ANGPTL4 as Potential Best-in-Disease Profile The first physiologic sink for excess triglycerides ANGPTL4 Inhibition (MAR001/5) APOC3 Inhibition (Olezarsen/Plozasiran) • Physiological adipose TG clearance • Forced hepatic TG clearance • No hepatic fat loadin

  10. Slide 10: TYDAL-TIMI Phase 2b: Establishing a Potential Best in Disease Profile

    TYDAL-TIMI 78 Phase 2b: Establishing a Potential Best in Disease Profile >60% T2DM/pre-DM informs metabolic safety profile; sHTG subgroup informs clinical activity Study Population (N=235) Key 12-week Topline Data Week 24 Day 1 Week 12: • Key Inclusion Criteria: Randomization Primary Endpoint • Appr

  11. Slide 11: MAR001: Emerging Clinical Data Supports Potential Best-in-Disease Profile

    MAR001: Emerging Clinical Data Supports Potential Best-in-Disease Profile MAR001/005 Olezarsen1 Plozasiran2,4,6, 7 -70% + -63 to -73% -79 to -81% TG Lowering Phase 2b, pooled 450/900 mg dose; >500 -27% pbo Phase 3 efficacy; median TG 793 mg/dL at Phase 3 efficacy; median TG 677 mg/dL at mg/dL subgro

  12. Slide 12: MAR001/5 Profile: Highly Differentiated; Compelling to Physicians; Large Potential Opportunity

    MAR001/5 Profile: Highly Differentiated; Compelling to Physicians; Represents Large Potential Opportunity +0.3 HbA1c difference could be HbA1c drives physician choice in Potential for 1/3 or more of a $10B clinically meaningful sHTG market • Even small, sustained HbA1c increases HbA1c stabilization

  13. Slide 13: As Predicted by Biology: ANGPTL4 Inhibition Overperforms in sHTG vs. mHTG

    As Predicted by Biology: ANGPTL4 Inhibition Overperforms in sHTG vs. mHTG TG lowering scales with baseline TGs: MAR001 is competitive with APOC3 inhibitors in severe patients -90% -80% MAR001 % TG change from baseline -70% APOC3: (Olezarsen, Plozasiran) -60% -50% -40% -30% -20% -10% 0% 50 250 450 65

  14. Slide 14: MAR-104 Study: Potential Best-in-Class Suppression of Postprandial TGs

    MAR-104 Study: Potential Best-in-Class Suppression of Postprandial TGs MAR001 flattens the post-prandial TG surge, the key driver of AP risk Key 12-week topline data Study Population (N=31) Day 1 Week 12: Week 24 • 42% reduction in TG AUC at 12 Randomization Primary Endpoint weeks for MAR001 vs. Pbo

  15. Slide 15: MAR002 for Acromegaly

    • Section IV MAR002 for Acromegaly First long-acting GHR antagonist candidate for acromegaly ©2023 Marea Therapeutics 15

  16. Slide 16: Acromegaly: Serious Disease with Inadequate Options for Medical Therapy

    Acromegaly: Serious Disease with Inadequate Options for Medical Therapy The Burden & Opportunity Two Approaches to Medical Therapy ~30K patients US Pituitary Gland • caused by excess GH production from benign pituitary adenoma. 1 Inhibit Secretion Early Mortality and High Morbidity (e.g., SRLs) • Bo

  17. Slide 17: Medical Therapy Treatment Guidelines: Direct Growth Hormone Antagonists Critical for >70% of Patients

    Medical Therapy Treatment Guidelines: Direct Growth Hormone Antagonists Critical for >70% of Patients IGF-1 > ULN after surgery ~80% lower IGF-1, favorable ~10-20% First Line T2DM, unfavorable tumor tumor histology, tumor histology • SRLs often initiated first for mass concerns tumor volume control

  18. Slide 18: The Marea Opportunity

    The Marea Opportunity Most patients are not fully controlled or cannot tolerate current therapies MAR002 (anti-GHR mAb) A Potential Optimal Direct GHRA Strong drive to treat patients to IGF-1 Goal • 2.5x mortality rate in patients who do not achieve IGF-1 >60% IGF-1 max suppression3 normalization1 •

  19. Slide 19: An Optimal Direct GHRA Could Address 3-4x More Patients than the SRL Class

    An Optimal Direct GHRA Could Address 3-4x More Patients than the SRL Class A better GHRA than Somavert is needed to address >9K patients SRLs: <30% Disease Control in GH Antagonist: >90% Disease Control Treatment-naïve patients (Somavert) (Paltusotine) 18% IGF > normal 77% The Marea opportunity (unc

  20. Slide 20: MAR002: Allosteric Mechanism, Potential for greater Efficacy than Somavert

    MAR002: Allosteric Mechanism, Potential for greater Efficacy than Somavert Maintains Potent GHR Antagonism at High GH Levels (Preclinical Data) No drug: increasing GH Growth hormone signaling leads to increased signaling Somavert: loses efficacy at high GH concentrations MAR002: maintains reduction

  21. Slide 21: Phase 1 Healthy Volunteer Study Established Potential Best-in-Class Profile

    Phase 1 Healthy Volunteer Study Established Potential Best-in-Class Profile Potential best-in-disease suppression; 300 mg Q2W predicted clinical dose Days at >45% IGF-1 Max IGF-1 Suppression in Healthy Volunteers (%) Suppression1 Phase 1 Study Design 80 50 43 70 64% Max IGF-1 Suppression (%) • Healt

  22. Slide 22: MAR002: Emerging Clinical Data Supports Potential Best-in-Class Profile

    MAR002: Emerging Clinical Data Supports Potential Best-in-Class Profile MAR002 Somavert Peak IGF-1 Suppression in HV -64% -49%1 In vitro potency 90% suppression 24% suppression2 with excess GH Allosteric mAb competitive peptide IGF-1 Expected > Somavert 81% IGF-1 normalization in patients3 Normaliza

  23. Slide 23: Efficient Development to POC to Evaluate 1st and 2nd Line Label

    Efficient Development to POC to Evaluate 1st and 2nd Line Label Phase 2 study population supports 1) first line monotherapy 2) second line combination therapy 3) second line monotherapy Study Population (N~72) 150 mg Q2W Key week-10 Topline Data All-Comers MAR002 - Untreated Active 300 mg Q2W • Asse

  24. Slide 24: Advancing a Late-Stage Cardioendocrine Pipeline Toward Potential 2026-27 Value Inflections

    Advancing a Late-Stage Cardioendocrine Pipeline Toward Potential 2026-27 Value Inflections Molecule Target Indication Disc IND-E Ph1 Ph2 Ph3 Anticipated Near-term Milestones MAR001 Phase 2b TYDAL (mHTG/sHTG) Q2 2026 ✓ • Phase 2/2b 12-week data Cardiometabolic H2 2026 • Phase 2/2b 24-week data MAR001

  25. Slide 25: Thank You

    Thank You ©2026 Marea Therapeutics, Inc. All rights reserved.

Marea Therapeutics — Investor Presentation (September 2026) on 6ix